The Cliches of R&D Day
Executive SummaryAttend any Big Pharma R&D day and you'll hear at least two common themes. First, that the development group has improved NDA submission timelines so dramatically that all of its drugs are moving from clinic to market faster than the average in the industry. And second, that the company's research focuses on the innovative--usually on the root causes, not symptomatic relief--of diseases for which there are at best inadequate treatments. We're not sure that either one of these notions can be swallowed undiluted.
You may also be interested in...
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
Progress is being made towards the implementation of the EU’s new patent system, but the UK’s insistence on severing all ties with the European Court could spell the end for its participation.
A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.